Recorded fact · drug.label_indication
drug.label_indication for encorafenib|metastatic-melanoma
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact e2d47bfd resolves to.
The record
| Fact id | e2d47bfd8da0c096f6530df9 |
|---|---|
| Entity | drug: encorafenib|metastatic-melanoma |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260226 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 3b8c089d2db4ad6c5473544b1af76a5bb1b3f3c3a6632e6f34d3808ea43ef5a1.
The value
{
"ingredient": "Encorafenib",
"conditionId": "metastatic-melanoma",
"conditionName": "Metastatic Melanoma",
"matchedAlias": "metastatic melanoma",
"context": "indication",
"brand": "BRAFTOVI",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "235dfc38-0f0b-4037-b501-7a9f4294740c",
"labelEffectiveTime": "20260226",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 1aa024a69d47a79575eebd6ae1d336e1bfc337095fe984dc9d3e8a07df779113.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.